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Abstract
Background: Malnutrition is a significant problem in patients with ovarian cancer. The goal of this
study was to investigate the prognostic role of Subjective Global Assessment (SGA) in patients with
ovarian cancer treated in an integrative cancer treatment setting.
Methods: We evaluated a case series of 132 ovarian cancer patients treated at Cancer Treatment
Centers of America® from Jan 2001 to May 2006. SGA was used to assess nutritional status at
baseline. Using SGA, patients were classified as well nourished (SGA A), moderately malnourished
(SGA B) or severely malnourished (SGA C). Kaplan Meier method was used to calculate survival.
Cox proportional hazard models were constructed to evaluate the prognostic effect of SGA
independent of other factors.
Results: Of 132 patients, 24 were newly diagnosed while 108 had received prior treatment. 15
had stage I disease at diagnosis, 8 stage II, 85 stage III and 17 stage IV. The median age at
presentation was 54.4 years (range 25.5 – 82.5 years). 66 patients were well-nourished (SGA A),
35 moderately malnourished (SGA B) and 31 severely malnourished (SGA C). Well nourished
patients had a median survival of 19.3 months (95% CI: 14.1 to 24.5), moderately malnourished 15.5
months (95% CI: 5.8 to 25.1), and severely malnourished 6.7 months (95% CI: 4.1 to 9.3); the
difference being statistically significant (p = 0.0003). Multivariate Cox modeling, after adjusting for
stage at diagnosis and prior treatment history found that moderately malnourished and severely
malnourished status were associated with a relative risk of 2.1 (95% CI: 1.2 to 3.6, p = 0.008) and
3.4 (95% CI: 1.9 to 5.8, p < 0.001) respectively as compared to well nourished status.
Conclusion: Univariate and multivariate survival analyses found that low SGA scores (i.e. well-
nourished status) are associated with better survival outcomes. This study lends support to the
role of aggressive nutritional intervention in improving patient outcomes in cancer care.
Background
The overall age-adjusted incidence rate for all ovarian can-
cer cases as reported by the Surveillance, Epidemiology,
and End Results (SEER) Program of the National Cancer
Institute is 16.23 cases per 100,000 women standardized
to the 2000 United States standard population [1]. Ovar-
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ian cancer is the fifth leading cause of cancer deaths in
women, the leading cause of death from gynecological
malignancy, and the second most commonly diagnosed
gynecologic malignancy in the United States [2,3]. Most
patients are diagnosed with regional and distant disease,
which have poor 5-year survival rates of 69% and 29%,
respectively [3].
Various clinical, biochemical and histological prognostic
factors for ovarian cancer have been identified. Age, stage,
grade, and cytology are important prognostic factors in
high-risk early-stage epithelial ovarian cancer [4,5]. Per-
formance status, tumor histology and residual tumor vol-
ume are independent predictors of prognosis in patients
with stage III epithelial ovarian cancer [5]. Additionally,
presence or absence of ascites and diameter of the largest
residual tumor nodule are statistically important predic-
tors of survival in ovarian cancer [6]. Furthermore, change
of body weight during primary chemotherapy has also
been reported as a strong prognostic factor [7]. Recently
nutritional status has been hypothesized to be of prognos-
tic value in patients with ovarian cancer [8].
Malnutrition in cancer patients is a significant problem
due to a variety of mechanisms involving the tumor, the
host response to the tumor, and anticancer therapies [9],
especially among those patients diagnosed with ovarian
cancer [10]. Malnutrition has been associated with a
number of clinical consequences, including reduced qual-
ity of life (QoL), decreased response to treatment,
increased risk of chemotherapy-induced toxicity and a
reduction in survival of cancer patients [11,12] ovarian
cancer being no exception [13]. The prevalence of malnu-
trition in patients with ovarian cancer has been reported
to an extent of 67% [14,15]. As malnutrition can affect the
treatment and outcomes of patients with ovarian cancer,
timely intervention to assess and improve nutritional sta-
tus in such patients is of utmost importance.
There are various methods of assessing nutritional status
in cancer, and each has its own advantages and disadvan-
tages. Among the most commonly used tools to measure
nutritional status are anthropometric and laboratory
measurements (e.g. weight change, arm muscle circumfer-
ence, triceps skinfold thickness, serum albumin, transfer-
rin assays and nitrogen balance studies) [16-21].
Anthropometric criteria alone are the most useful to assess
chronic malnutrition, as alterations in body composition
occur later during the malnutrition process [22]. Some of
the objective measures such as serum albumin are likely to
be influenced by many non-nutritional factors [23-25].
The interpretation of these measures is often difficult
because non-nutritional factors, such as hydration state
and disease process, can obscure the effects of actual nutri-
ent deprivation [26]. Furthermore, some objective indica-
tors such as serum albumin have long half-lives, thus,
assessing changes in the nutritional status over a short
period of time is challenging. In an effort to overcome the
problems of traditional nutritional assessment, an easy-
to-use, inexpensive, and non-invasive clinical instrument
has been developed – the Subjective Global Assessment
(SGA).
The SGA is a clinical technique that combines data from
subjective and objective aspects of medical history
(weight change, dietary intake change, gastrointestinal
symptoms, and changes in functional capacity) and phys-
ical examination (loss of subcutaneous fat, muscle wast-
ing, ankle or sacral edema and ascites) [27]. After
evaluation, patients are categorized into three distinct
classes of nutritional status; well nourished (SGA A),
moderately malnourished (SGA B) and severely malnour-
ished (SGA C). The SGA has been validated in a number
of diverse patient populations, including cancer patients
[28-36]. It has also been correlated with a number of
objective nutritional assessment indicators, morbidity,
mortality, and QoL measures [23,27,34,37-40]. To the
best of our knowledge, no studies conducted to date have
evaluated the prognostic significance of SGA in ovarian
cancer.
The primary objective of this study is to evaluate the prog-
nostic significance of the SGA in patients with ovarian
cancer treated in an integrative cancer treatment setting
Methods
Study Sample
A retrospective chart review was performed on a consecu-
tive case series of 132 ovarian cancer patients treated at
Cancer Treatment Centers of America® (CTCA) at Mid-
western Regional Medical Center (MRMC) between Janu-
ary 01 and May 06. None of these patients had received
any treatment at MRMC when enrolled in this investiga-
tion. The patients were identified from the MRMC tumor
registry. Only patients with a histologically confirmed
diagnosis of ovarian cancer were included in this study.
The SGA was used to assess nutritional status. All patients
in this study were scheduled for a consultation with a die-
titian. Prior to each consultation, a dietitian reviewed the
patient's history from the medical record and verified the
patient's current weight. During the consultation, the die-
titians reviewed the SGA instrument with the patient to
obtain answers to all the questions. The dietitians also
completed a physical exam paying particular attention to
loss of subcutaneous fat, muscle wasting, presence of
ankle and sacral edema and ascites. After the consultation,
the dietitians ranked the patient's nutritional status as
well nourished (SGA A), moderately malnourished (SGA
B) or severely malnourished (SGA C) as described by Det-Journal of Ovarian Research 2008, 1:5 http://www.ovarianresearch.com/content/1/1/5
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sky et al [27]. For the purpose of this analysis, malnutri-
tion was defined as either SGA B or SGA C.
Prespecified Baseline Clinical Factors
Baseline clinical factors that were assessed for prognostic
significance were age at presentation, stage of disease at
diagnosis and prior treatment history. The prior treatment
history variable categorized patients into those who have
received definitive cancer treatment elsewhere before
coming to our institution and those who were newly diag-
nosed at our institution. The only follow-up information
required was the date of death or the date of last contact/
last known to be alive. This study was approved by the
Institutional Review Board at Midwestern Regional Medi-
cal Center.
Data Analysis and Statistical Methods
All data were analyzed using SPSS 11.5 (SPSS Inc., Chi-
cago, IL, USA). Patient survival was defined as the time
interval between date of first patient visit to the hospital
and date of death from any cause or date of last contact/
last known to be alive. The Kaplan-Meier or product-limit
method was used to calculate survival. The log rank test
statistic was used to evaluate the equality of survival dis-
tributions across different strata. A difference was consid-
ered to be statistically significant if the p value was less
than or equal to 0.05. Survival was also evaluated using
univariate and multivariate Cox regression analysis. Vari-
ables evaluated included SGA, age at presentation, prior
treatment history, and stage at diagnosis. For the purpose
of this analysis, stage at diagnosis variable was treated as a
dichotomous variable with 2 categories – early stage
(stages I and II) and late stage (stages III and IV).
Results
At the time of this analysis (June 08), 91 patients had
expired and 41 were censored, as shown in Table 1. The
cut-off date for the follow-up for all participants was June
08. The median age at presentation was 54.4 years (range
25.5 – 82.5 years). 66 patients were well nourished (SGA
A), 35 were moderately malnourished (SGA B) and 31
were severely malnourished (SGA C). Of 24 analytic
patients, 9 (37.5%) were well-nourished while 57
(52.8%) of 108 non-analytic patients were well-nour-
ished, the difference being statistically non-significant (p
= 0.32). Of 23 early-stage (stage I and II) patients, 13
(56.5%) were well-nourished while 51 (50.0%) of 102
late-stage (stage III and IV) patients were well-nourished,
the difference being statistically non-significant (p =
0.20).
Table 2 shows the univariate survival analysis of different
prognostic factors. SGA and treatment history were found
to be statistically significantly associated with survival.
Stage at diagnosis was found to be marginally significant
and it was decided to control for it in the multivariate
analysis. Age at presentation and BMI were not found to
be statistically significantly associated with survival and
were therefore not considered further.
Figure 1 shows the survival curves for the 3 categories of
SGA. Well nourished patients had a median survival of
19.3 months (95% CI: 14.1 to 24.5), moderately mal-
nourished 15.5 months (95% CI: 5.8 to 25.1), and
severely malnourished 6.7 months (95% CI: 4.1 to 9.3);
the difference being statistically significant (p = 0.0003).
Table 3 summarizes the results of multivariate Cox regres-
sion analyses. Multivariate Cox modeling, after adjusting
Table 1: Patient Characteristics
Characteristic Categories Number Percent (%)
Vital Status Expired 91 68.9
Censored1 41 31.1
Prior Treatment History Progressive disease 108 81.8
Newly diagnosed 24 18.2
Stage at Diagnosis Stage I 15 11.4
Stage II 8 6.1
Stage III 85 64.4
Stage IV 17 12.9
Missing 7 5.3
Age at Presentation Mean 53.4
Median 54.4
Range 25.5 – 82.5
SGA A 66 50
B3 5 2 6 . 5
C3 1 2 3 . 5
1Patients who reached the end of their follow-up without experiencing death.
N = 132Journal of Ovarian Research 2008, 1:5 http://www.ovarianresearch.com/content/1/1/5
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for stage at diagnosis and prior treatment history found
that moderately malnourished status was associated with
a relative risk of 2.1 (95% CI: 1.2 to 3.6, p = 0.008) as
compared to well nourished status. Similarly, severely
malnourished status was associated with a relative risk of
3.4 (95% CI: 1.9 to 5.8, p < 0.001) as compared to well
nourished status. Prior treatment history and stage at diag-
nosis were also found to be statistically significantly asso-
ciated with survival independent of SGA as shown in
Table 3. It was interesting to see that stage at diagnosis
which was marginally significant upon univariate analysis
became statistically significant upon multivariate analysis.
Table 4 shows statistically distinct prognostic classes of
our patient cohort. Stratum 1 has no median survival
because all 3 observations were censored.
Discussion
The identification of prognostic factors in ovarian cancer
is of considerable importance for the clinical management
of the disease. While nutritional status has been hypothe-
sized to have an association with survival, the published
literature documenting its prognostic significance in ovar-
ian cancer remains sparse. Despite the number of nutri-
tion assessment tools used for research purposes, a
consensus has not been reached on what may be the "gold
standard" for nutritional assessment in cancer. The cur-
rent study was undertaken to investigate if SGA, a poten-
tial indicator of nutritional status, could predict survival
in ovarian cancer.
In this study, we found that SGA A (well-nourished status)
versus SGA B/C (moderate to severe malnourished status)
identified patients with better survival outcomes. We
found that the SGA provides useful prognostic informa-
tion in patients with ovarian cancer. In a clinical setting,
the SGA is invaluable in identifying malnourished
patients in a quick and non-invasive manner. Moreover,
the simplicity of use of the SGA also enables health pro-
fessionals other than oncologists and dietitians to accu-
rately assess the patient's nutritional status. In our
previous study conducted in colorectal cancer, we found
SGA to be a significant predictor of survival. The median
survival of patients with SGA A was 12.8 months (95% CI;
9.1–16.5), those with SGA B was 8.8 months (95% CI;
6.7–10.9) and those with SGA C was 6 months (95% CI;
3.9–8.1) [41].
SGA is simple, safe and inexpensive, which renders it a
universal tool for nutritional assessment. SGA differs from
other nutritional assessment methods in that it is the only
one that evaluates functional capacity [42]. SGA has
gained acceptance among investigators and it is now used
as a benchmark to validate new assessment methods, such
as bioelectrical impedance analysis [43] and mid-upper
arm anthropometry. One of the major criticisms of the
method is that its accuracy depends on the observer's
experience. Although SGA depends on the interviewer's
training and on the interpretation of the collected data, its
subjectivity may be minimized by assigning points to
questionnaire items [36]. Another criticism directed at
SGA is that it is a subjective method with only three cate-
gories, which does not allow assessment of nutritional
scale on a continuum [42]. Despite these disadvantages,
SGA continues to be a good option for assessing nutri-
tional status in several clinical conditions.
This study, because of its retrospective nature, relies on
data not primarily meant for research. We think that
restricting the analysis to newly diagnosed patients
(patients with no prior treatment history) would have
been more accurate, since it would have allowed for eval-
uation of true overall survival time i.e. time from the date
of diagnosis to the date of death. However, doing so
would have caused a significant reduction in the sample
size. In our study, the survival time was calculated from
the day of first visit at our hospital because information
on SGA was not available at the time of diagnosis for pre-
viously treated patients. This drawback emphasizes the
need for conducting prospective studies having nutri-
Table 2: Univariate Kaplan-Meier Survival Analysis
Variable Median survival in months Log-rank score P-value
SGA
• Well nourished 19.3 (14.1 to 24.5) 15.9 0.0003
• Moderately malnourished 15.5 (5.8 to 25.1)
• Severely malnourished 6.7 (4.1 to 9.3)
Tumor Stage
• Stage I and II 23.9 (7.7 to 40.3) 3.3 0.07
• Stage III and IV 15.5 (10.0 to 20.9)
Treatment History
• Newly diagnosed 43.1 (18.1 to 68.1) 13.5 0.0002
• Progressive disease 12.1 (7.2 to 17.1)
N = 132Journal of Ovarian Research 2008, 1:5 http://www.ovarianresearch.com/content/1/1/5
Page 5 of 7
(page number not for citation purposes)
tional information available since the date of diagnosis. A
majority of our patients had advanced stage disease and
had failed primary treatment elsewhere before coming to
our hospital. As a result, generalizability of the study find-
ings to cancer patients with early-stage disease might be
questionable. However, we have no reasons to believe
that patients with early-stage disease will display different
findings. This study did not evaluate the effectiveness of
nutritional intervention on survival and future prospec-
tive studies should attempt to address this important
research question. The SGA, being a subjective method,
relies on the observer's ability to collect and interpret
information, and as a result, is likely to suffer from
observer bias. No assessment of inter-rater reliability of
the users of the SGA was made in this study. This bias,
however, was minimized by restricting the use of the SGA
to well-trained dietitians with an expertise in the use of
this clinical instrument.
Survival stratified by 3 categories of SGA Figure 1
Survival stratified by 3 categories of SGA. Each drop in a probability curve indicates one or more events in that group. 
Vertical lines indicate censored patients, i.e., those who reached the end of their follow-up without experiencing death.
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Table 3: Multivariate Cox Proportional Hazard Model
Independent Variable Unit of increase RR1 95% CI P-value
Moderately malnourished Well-nourished as referent 2.1 1.2, 3.6 0.008
Severely malnourished Well-nourished as referent 3.4 1.9, 5.8 < 0.001
Stage at Diagnosis Stage I and II as referent 2.1 1.1, 4.0 0.02
Treatment History Newly Diagnosed as referent 4.8 2.4, 9.7 < 0.001
1Relative risk (Cox proportional hazard)
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Conclusion
In summary, our study has demonstrated the prognostic
significance of SGA in ovarian cancer. To the best of our
knowledge, this is the first study to evaluate SGA for its
prognostic importance in ovarian cancer patients treated
in an integrative cancer treatment setting.
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